Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Nicorandil, Diltiazem or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts - a Pilot Randomized Controlled Trial

Next Previous
Trial Profile

Effect of Nicorandil, Diltiazem or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts - a Pilot Randomized Controlled Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diltiazem (Primary) ; Isosorbide mononitrate (Primary) ; Nicorandil (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms ASRAB-Pilot

Most Recent Events

  • 01 Jul 2023 Status changed from active, no longer recruiting to completed.
  • 16 Feb 2023 Planned End Date changed from 1 Mar 2023 to 1 Jun 2023.
  • 16 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 May 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top